Send feedback

MECP2 p.Ser146Phe

c.437C>T · rs61748390 · VCV143563

Pathogenic Expert panel
Classification
Pathogenic
ClinVar
Review
Expert panel ★★★☆
ClinVar · 4 submitters
AlphaMissense
likely pathogenic
0.9999 · ACMG-weighted
gnomAD v4.1
Absent
absent from gnomAD v4.1
Missense predictors
3/3 damaging
AlphaMissense, REVEL, SaProt
Conditions
1
Rett syndrome

ClinGen expert panel — Rett and Angelman-like Disorders VCEP

Pathogenic for Rett syndrome. Applied ACMG criteria (verbatim):

PM2_Supporting PS2 PS4_Moderate PM1 PP3 PP4 PM5

Curation rationale (ClinGen, verbatim)

The p.Ser134Phe variant in MECP2 (NM_004992.3) has been reported as a de novo occurrence (biological parentage both confirmed and unconfirmed) in at least 2 individuals with Rett syndrome (PMID 15737703, internal database - GeneDx) (PS2, PP4). The p.Ser134Phe variant has been observed in at least 1 other individual with Rett syndrome (PMID 21160487) (PS4_moderate). A pathogenic missense variant (p.Ser134Cys) has been previously identified within this codon which indicates that this residue is critical to the function of the protein (PMID 10814718, 11738864, 17089071, 12655490, 21160487, 11738883, 18337588, 10767337, 23696494, 22182064) (PM5). The p.Ser134Phe variant occurs in the well-characterized methyl-binding domain (MBD) functional domain of MECP2 (PMID 1326358, 23770565) (PM1). The p.Ser134Phe variant in MECP2 is absent from gnomAD (PM2_supporting). Computational prediction analysis tools suggests a deleterious impact; however, this information does not predict clinical significance on its own (PP3). In summary, the p.Ser134Phe variant in MECP2 is classified as Pathogenic for Rett syndrome based on the ACMG/AMP criteria (PS2, PS4_moderate, PM1, PM5, PM2_supporting, PP3, PP4).

ClinGen Evidence Repository → · reported verbatim, not re-tallied by Sugi Variant.

Computational evidence

Protein change
AlphaMissense0.9999likely pathogenic ✓ concordant with ClinVar · top 5% in MECP2
REVEL0.991strongly pathogenic-leaning
SaProtLLR -14.13damaging
⇒ AlphaMissense, REVEL and SaProt all call this damaging.
Splicing
SpliceAI—not assessed · no allele here is in the release
Constraint at this position
ConservationphyloP 12GERP 1.1, phastCons 1
Regional constrainto/e 0.11constrained · MANE · 886 bp · p 9.6e-08 · regional, not allelic
Overall
CADD26.8PHRED · no single calibrated threshold — expert panels disagree

AlphaMissense carries the ACMG weight for missense; REVEL and SaProt are independent agreement signals.

⚠ Isoform check: AlphaMissense numbered on a different transcript (AM S134F vs ClinVar S146F) — verify the residue.

Population frequency

gnomAD v4.1 · exomes + genomes

Absent from gnomAD v4.1. Not observed in any sequenced alleles — a rarity signal (ACMG PM2-supporting), not evidence of pathogenicity on its own.

Variant & gene context

Gene
MECP2
Protein
p.Ser146Phe
Coding
c.437C>T
MANE Select
NM_001110792
dbSNP
rs61748390
Type
single nucleotide variant
Location
chrX:154031427 (GRCh38)
Structure
AlphaFold pLDDT 57.25 · 11 PDB
Residue 134 UniProt numbering
the mbd domain; a β-strand; a UniProt-annotated variant site (in rtt)
Full MECP2 gene report on Sugi Atlas → Gene function, pathways, protein structure, interactions & more

Disease context

Rett syndrome — disease report on Sugi Atlas → Associated genes, phenotypes, clinical trials & treatments

For Rett syndrome (Orphanet):

Inheritance
X-linked dominant
Onset
Infancy
Prevalence
1-9 / 100 000 (Europe)

Similar variants

Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →

Cite Sugi Variant

Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/mecp2-p-ser146phe (accessed [today's date]).

Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown